KRAS

Test for KRAS mutation
#Bayer #KRAS #Kumquat Biosciences #Oncology #Precision medicine

Bayer and Kumquat collaborate on precision oncology

Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.   Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities.  Kumquat received US Food… Read More

#Business & Investment #Cancer Research #News

Test for KRAS mutation
#Antibody #Combination therapy #KRAS #Oncology #University of California San Francisco

Precision drug, antibody and radiation therapy kills tumours

Scientists have found a way to combine a precision drug therapy with an antibody and radiation to eliminate tumours without causing side effects.  “This is a one-two punch,” said Charly Craik, Professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF) and co-senior author of the… Read More

#News #Trending News

Treg cells
#Amsterdam University Medical Centre #KRAS #Lung cancer #Oncology #The Francis Crick Institute #Tregs

Tregs block immune response in lung cancer, study finds

Researchers at the Francis Crick Institute, working with the Amsterdam University Medical Centre, have found that immune cells are held back from fighting lung tumours by another type of cell. Drugs that block a cancer-causing protein called KRAS-G12C are approved for use in lung cancer but… Read More

#Cancer Research #News

Colorectal cancer
#AACR #Cancer research #Cardiff Oncology #Clinical trials #Colorectal cancer #KRAS

Promising data for onvansertib in combination with standard-of-care  

Findings from Cardiff Oncology’s Phase Ib portion of the Phase Ib/II study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC) have been published in Clinical Cancer Research, a journal of the American Association for Cancer Research.  The publication underscores the safety… Read More

#Cancer Research #News

#Cancer #Gene mutation #KRAS

Lumykras receives MHRA approval in the UK for lung cancer patients  

Amgen UK’s first-in-class medicine sotorasib (a targeted KRAS G12C inhibitor formerly named AMG 510) has become the first new cancer therapy to receive Conditional Marketing Authorisation for use1 across England, Scotland and Wales by the Medicines and Healthcare products Regulatory Agency (MHRA) under Project Orbis. This authorisation follows a review of sotorasib’s role in treating patients with… Read More

#News #Trending News